How to accelerate the supply of vaccines to all populations worldwide? Part II: Initial industry lessons learned and detailed technical reflections leveraging the COVID-19 situation. Issue 9 (23rd February 2022)

• Record Type: Journal Article
• Authors: McGoldrick, Mic; Gastineau, Thierry; Wilkinson, Diane; Campa, Cristiana; De Clercq, Norbert; Mallia-Milanes, Andrea; Germay, Olivier; Krishnan, Jyothsna; Van Ooij, M; Thien, Michael P; Mlynarczyk, Peter J.; Saltus, Edward; Wauters, Florence; Juvin, Philippe; Clenet, Didier; Basso, Ana; Dellepiane, Nora; Pagliusi, Sonia; Collaço de Moraes Stávale, Monique; Sivaramakrishnan, Venkatraman H; Desai, Samir
• Is Part Of: Vaccine. Volume 40:Issue 9(2022)
• Page Start: 1223
• Page End: 1230
• Publication Date: 2022-02-23
• Subjects: Regulatory Convergence -- Streamline -- Vaccine -- Reliance -- Harmonization -- Covid-19 -- Science-based -- Risk-based -- Digital; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2021.12.038
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Vaccine discovery and vaccination against preventable diseases are one of most important achievements of the human race. While medical, scientific & technological advancements have kept in pace and found their way into treatment options for a vast majority of diseases, vaccines as a prevention tool in the public health realm are found languishing in the gap between such innovations and their easy availability/accessibility to vulnerable populations. This paradox has been best highlighted during the unprecedented crisis of the COVID-19 pandemic. As part of a two series publication on the vaccine industry's view on how to accelerate the availability of vaccines worldwide, this paper offers a deep dive into detailed proposals to enable this objective. These first-of-its-kind technical proposals gleaned from challenges and learnings from the COVID-19 pandemic are applicable to vaccines that are already on the market for routine pathogens as well as for production of new(er) vaccines for emerging pathogens with a public health threat potential. The technical proposals offer feasible and sustainable solutions in pivotal areas such as process validation, comparability, stability, post-approval changes, release testing, packaging, genetically modified organisms and variants, which are linked to manufacturing and quality control of vaccines. Ultimately these proposals aim to ease high regulatory complexity and heterogeneity surrounding the manufacturing & distribution of vaccines, by advocating the use of (1) Science and Risk based approaches, (2) global regulatory harmonization, (3) use of reliance, work-sharing, and recognition processes and (4) digitalization. Capitalizing & collaborating on such new-world advancements into the science of vaccines will eventually benefit the world by turning vaccines into vaccination, ensuring the health of everyone.